FTC Clears AbbVie To Proceed With $10.1B ImmunoGen Buy

By Craig Clough · February 9, 2024, 5:07 PM EST

The 30-day waiting period for U.S. antitrust enforcers to review AbbVie's $10.1 billion purchase of ImmunoGen came and went without a move to deepen the investigation or challenge the deal, clearing...

To view the full article, register now.